Influenza Caused by the Novel Influenza A (H1N1) Virus

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

NCT00938639 | PHASE 2 | INTERVENTIONAL

The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.

1 Sites

240 Participants

Recruiting

18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Adelaide,South Australia,Australia,5000

Study Eligibility Criteria

Inclusion Criteria

* Male or female aged \>= 18 to \< 65 years at the time of providing informed consent.

Exclusion Criteria

* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.

Additional Studies

Additional studies can be found at ClinicalTrials.gov